×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
HCM – hutchmed (china) limited - american depositary shares (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
HCM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/5
11:00 pm
hcm
HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
Low
Report
HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
11/4
11:14 pm
hcm
HUTCHMED (China) Limited (NASDAQ: HCM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
HUTCHMED (China) Limited (NASDAQ: HCM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
10/31
04:38 am
hcm
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda [Yahoo! Finance]
Medium
Report
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda [Yahoo! Finance]
10/31
04:30 am
hcm
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
Medium
Report
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
10/16
12:30 am
hcm
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
Medium
Report
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
9/24
03:00 am
hcm
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
Medium
Report
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
9/8
08:00 pm
hcm
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer
Low
Report
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer
8/30
12:33 am
hcm
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China [Yahoo! Finance]
Medium
Report
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/6
06:04 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Nov 06
Low
Report
Form 6-K HUTCHMED (China) Ltd For: Nov 06
10/31
06:05 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Oct 31
Medium
Report
Form 6-K HUTCHMED (China) Ltd For: Oct 31
10/21
06:29 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Oct 21
Low
Report
Form 6-K HUTCHMED (China) Ltd For: Oct 21
10/16
06:20 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Oct 16
Medium
Report
Form 6-K HUTCHMED (China) Ltd For: Oct 16
9/24
06:09 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Sep 24
Medium
Report
Form 6-K HUTCHMED (China) Ltd For: Sep 24
9/9
06:13 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Sep 09
Low
Report
Form 6-K HUTCHMED (China) Ltd For: Sep 09
8/30
06:13 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Aug 30
Medium
Report
Form 6-K HUTCHMED (China) Ltd For: Aug 30
8/22
06:11 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Aug 22
Low
Report
Form 6-K HUTCHMED (China) Ltd For: Aug 22
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/13
HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating.
10.3%
10/11 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.0%
4/22 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.2%
9/30 CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term 4.9%
2/6 Chi-Med Announces the Exercise of Underwriters’ Over-allotment Option for Public Offering of ADSs 3.8%
7/30 Hutchison China MediTech Limited 2019 Q2 - Results - Earnings Call Slides [Seeking Alpha] 3.2%
4/17 Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors 3.1%
10/23 HUTCHISON CHINA/S (NASDAQ: HCM) is now covered by analysts at Bank of America Corp. They set a "buy" rating on the stock. 3.1%
1/13 Chi-Med Initiates a Phase II Trial of Surufatinib in Combination with Tuoyi in Patients with Advanced Solid Tumors 2.9%
3/3 Hutchison China MediTech Limited (HCM) Q4 2019 Earnings Call Transcript [The Motley Fool] 2.9%
10/11 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.0%
4/22 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.2%
9/30 CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term 4.9%
2/6 Chi-Med Announces the Exercise of Underwriters’ Over-allotment Option for Public Offering of ADSs 3.8%
7/30 Hutchison China MediTech Limited 2019 Q2 - Results - Earnings Call Slides [Seeking Alpha] 3.2%
4/17 Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors 3.1%
10/23 HUTCHISON CHINA/S (NASDAQ: HCM) is now covered by analysts at Bank of America Corp. They set a "buy" rating on the stock. 3.1%
1/13 Chi-Med Initiates a Phase II Trial of Surufatinib in Combination with Tuoyi in Patients with Advanced Solid Tumors 2.9%
3/3 Hutchison China MediTech Limited (HCM) Q4 2019 Earnings Call Transcript [The Motley Fool] 2.9%
TOP News Decliners
6/27
Chi-Med Announces Secondary Offering of American Depositary Shares
-18.8%
3/18 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -17.4%
1/21 Chi-Med Announces Proposed Public Offering of ADSs -12.6%
1/23 Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs -9.8%
7/20 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -7.7%
9/3 Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma -5.3%
12/30 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -3.4%
2/25 Chi-Med to announce 2019 Final Results on Tuesday, March 3, 2020 – adjustment to announcement and presentation logistics due to travel restrictions -3.3%
9/27 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -2.9%
6/14 Chi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early -2.7%
3/18 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -17.4%
1/21 Chi-Med Announces Proposed Public Offering of ADSs -12.6%
1/23 Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs -9.8%
7/20 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -7.7%
9/3 Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma -5.3%
12/30 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -3.4%
2/25 Chi-Med to announce 2019 Final Results on Tuesday, March 3, 2020 – adjustment to announcement and presentation logistics due to travel restrictions -3.3%
9/27 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -2.9%
6/14 Chi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early -2.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: